Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...
An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback